title: Does the use of recombinant AAV2 in pulmonary gene therapy damage lung function?
abstract: Forty-eight BALB/c mice were divided into two groups of 24 animals each. In the control group (CTRL) saline was intratracheally instilled, while the virus group (VR) received rAAV2-GFP (4 x 10(9) particles). These groups were subdivided into four sub-groups (n=6). Pulmonary mechanical parameters were analyzed after 3 weeks (VR1d3w) and at 1 (VR2d1w), 2 (VR2d2w) and 3 weeks (VR2d3w) after a second AAV2 dose. Fractions of the area of alveolar collapse and the amount of polymorpho- and mononuclear cells were determined by point-counting technique. Viral transduction was evaluated by immunohistochemistry. Lung mechanical data were similar in all groups. However, there was an increase in airway and lung parenchyma cellularity and in the fraction of area of alveolar collapse in the VR2d2w group, which nonetheless decreased with time. There was no evidence of apoptosis in any group. In conclusion, the gene transfer vector AAV2 induces, in the lung, a discrete inflammatory reaction that does not affect either baseline lung mechanics or airway hyperresponsiveness.
authors.affiliation: Laboratory of Cellular and Molecular Physiology, University of Rio de Janeiro, Centro de Ciências da Saúde, Ilha do Fundão, 21949-900 Rio de Janeiro, Brazil.
authors.forename: Roberta M
authors.initials: RM
authors.lastname: Lassance
authors.forename: Caroline P
authors.initials: CP
authors.lastname: Pássaro
authors.forename: Sabrina V
authors.initials: SV
authors.lastname: Martini
authors.forename: Raquel C
authors.initials: RC
authors.lastname: Castiglione
authors.forename: Tatiana M
authors.initials: TM
authors.lastname: Gutierrez
authors.forename: Soraia C
authors.initials: SC
authors.lastname: Abreu
authors.forename: Mariana A
authors.initials: MA
authors.lastname: Antunes
authors.forename: Debora G
authors.initials: DG
authors.lastname: Xisto
authors.forename: Liudmila
authors.initials: L
authors.lastname: Cebotaru
authors.forename: Hilda
authors.initials: H
authors.lastname: Petrs-Silva
authors.forename: Walter A
authors.initials: WA
authors.lastname: Zin
authors.forename: William B
authors.initials: WB
authors.lastname: Guggino
authors.forename: Rafael
authors.initials: R
authors.lastname: Linden
authors.forename: Patricia R M
authors.initials: PR
authors.lastname: Rocco
authors.forename: Marcelo M
authors.initials: MM
authors.lastname: Morales
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001993:Bronchodilator Agents / Q000494:pharmacology; D000229:Dependovirus / Q000235:genetics*; D015316:Genetic Therapy / Q000009:adverse effects*; D005822:Genetic Vectors / Q000009:adverse effects*; D049452:Green Fluorescent Proteins / Q000235:genetics; D007150:Immunohistochemistry; D008168:Lung / Q000473:pathology / Q000502:physiology*; D016210:Methacholine Chloride / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D012313:RNA / Q000235:genetics / Q000302:isolation & purification; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D015656:Respiratory Mechanics / Q000502:physiology; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D001993:Bronchodilator Agents; D012333:RNA, Messenger; D016210:Methacholine Chloride; D049452:Green Fluorescent Proteins; D012313:RNA